Notice of Refund | Feb 19, 2019 | PAPER | BOARD |
Motion for Refund of Post-Institution Fee | Jan 17, 2019 | PAPER | PETITIONER |
DECISION
Granting Petitioner’s Request to Withdraw Its Request for Rehearing
37 C.F.R. § 42.71 | Jan 16, 2019 | PAPER | BOARD |
Exhibit 3001 | Jan 16, 2019 | EXHIBIT | BOARD |
Petitioner's Updated Mandatory Notice | Jan 31, 2018 | PAPER | PETITIONER |
Patent Owner's Updated Mandatory Notice | Dec 27, 2017 | PAPER | PATENT OWNER |
PETITIONER'S REQUEST FOR REHEARING | Dec 12, 2017 | PAPER | PETITIONER |
Decision - Denying Institution of Inter Partes Review | Nov 13, 2017 | PAPER | BOARD |
Ex 2001 Non-Institution Decision in IPR2015-00418 | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2002 Ad-Ismail, Combinations Chemotherapy including Epirubicin | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2003 Hiddemann, Non-Hodgkin's Lymphomas | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2004 Vose, Diagnosis and Treatment of Non-Hodgkin's Lymphoma of Adults | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2005 Restriction Requirement dated Oct. 15, 2009 | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2006 Applicant's Election dated Jan. 29, 2010 | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Schein, Non-Hodgkin's Lymphoma: Patterns of Relapse from Complete Remission | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2010 Cabanillas, Clinical, Biologic, and Histologic Features of Late Relapses | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2012 Ezdinli, The Effect of Intensive Intermittent Maintenance Therapy | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2013 Van Oers, Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's Lymphoma | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2015 Arranz, Role of Interferon Alfa-2b in the Induction and Maintenance Treatment of Low-Grade Non-Hodgkin's Lymphoma | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2016 Dana, A Randomized Study of Alpha-Interferon Consolidation | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2017 Peterson, Cyclophosphamide vs Cyclophosphamide Plus Interferon Alfa-2b | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2018 Chisesi, Randomized Study of Chlorambucil | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2019 Rohatiner, Meta-Analysis to Evaluate the Role of Interferon | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2020 Davis, Therapy of B Cell Lymphoma with anti-CD20 antibodies | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2021 Multani, Monoclonal Antibody-Based Therapies | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2023 Carlson, Rituximab plus CHOP | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2025 Czuczman, Chemoimmunotherapy of Low-Grade Lymphoma | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2026 Grossbard, American Cancer Society Atlas of Clinical Oncology | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2027 Aviles, The Role of Interferon as Maintenance Therapy in Malignant Lymphoma | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2029 Grillo-Lopez, Treatment Options for Patients with Relapsed Low-Grade Follicular Lymphoma | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2030 Pickup, Clinical Pharmacokinetics of Prednisone and Prednisolone | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2031 Martelli, Current Guidelines for the Management of Aggressive Non-Hodgkin's Lymphoma | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2032 Meyer, Phase I Trial of Standard and Cyclophosphamide Dose-Escalated CHOP | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2033 Janeway, Chapter 9:The Humoral Immune Response | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2034 Maloney, Phase I Clinical Trial sing Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2035 Horning, Treatment Approaches to the Low-Grade Lymphomas | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2036 Chen, Synergistic Anti-proliferative Effect of Metformin and Sorafenib on Growth of Anaplastic Thyroid Cancer Cell | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2037 Dudeja, Synergy of Water Soluble Prodrug Triptolide | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2038 Understanding Maintenance Therapy | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2039 Grossbard, The McLaughlin Article Reviewed | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2040 Wang, The Synergistic In Vitro and In Vivo Antitumor Effect of Combination Therapy | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2041 Excerpts from Physicians' Desk Reference, Edition 52 | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Ex 2042 Song Declaration | Aug 15, 2017 | EXHIBIT | PATENT OWNER |
Patent Owner's Preliminary Response | Aug 15, 2017 | PAPER | PATENT OWNER |
Patent Owner's Exhibit List | Aug 15, 2017 | PAPER | PATENT OWNER |
EXPUNGED | May 15, 2017 | PAPER | BOARD |
Notice of Accord Filing Date | May 15, 2017 | PAPER | BOARD |
Power of Attorney | May 15, 2017 | PAPER | PATENT OWNER |
Patent Owner's Mandatory Notice | May 15, 2017 | PAPER | PATENT OWNER |
POA on behalf of Pfizer Inc. | Apr 21, 2017 | PAPER | PETITIONER |
Pat No. 8329172 | Apr 21, 2017 | EXHIBIT | PETITIONER |
McNeil | Apr 21, 2017 | EXHIBIT | PETITIONER |
1997 Rituxan Label | Apr 21, 2017 | EXHIBIT | PETITIONER |
Hochster I | Apr 21, 2017 | EXHIBIT | PETITIONER |
McLaughlin | Apr 21, 2017 | EXHIBIT | PETITIONER |
Sriskandan | Apr 21, 2017 | EXHIBIT | PETITIONER |
Maloney | Apr 21, 2017 | EXHIBIT | PETITIONER |
Aviles | Apr 21, 2017 | EXHIBIT | PETITIONER |
Steward | Apr 21, 2017 | EXHIBIT | PETITIONER |
Unterhalt | Apr 21, 2017 | EXHIBIT | PETITIONER |
180 Provisional | Apr 21, 2017 | EXHIBIT | PETITIONER |
956 Prelim Amendment | Apr 21, 2017 | EXHIBIT | PETITIONER |
956 Office Action | Apr 21, 2017 | EXHIBIT | PETITIONER |
Portlock | Apr 21, 2017 | EXHIBIT | PETITIONER |
Mark Benyunes Declaration | Apr 21, 2017 | EXHIBIT | PETITIONER |
Hochster II | Apr 21, 2017 | EXHIBIT | PETITIONER |
Hiddeman II | Apr 21, 2017 | EXHIBIT | PETITIONER |
Foon | Apr 21, 2017 | EXHIBIT | PETITIONER |
Campbell | Apr 21, 2017 | EXHIBIT | PETITIONER |
Skarin | Apr 21, 2017 | EXHIBIT | PETITIONER |
Scott Bennett Declaration | Apr 21, 2017 | EXHIBIT | PETITIONER |
Hiddemann I. | Apr 21, 2017 | EXHIBIT | PETITIONER |
Bishop | Apr 21, 2017 | EXHIBIT | PETITIONER |
956 Spec | Apr 21, 2017 | EXHIBIT | PETITIONER |
956 8-25-10 Remarks | Apr 21, 2017 | EXHIBIT | PETITIONER |
956 Notice of Allowance | Apr 21, 2017 | EXHIBIT | PETITIONER |
Hoppe | Apr 21, 2017 | EXHIBIT | PETITIONER |
956 10-28-11 Remarks | Apr 21, 2017 | EXHIBIT | PETITIONER |
IPR2015-00418 Prelim Resp | Apr 21, 2017 | EXHIBIT | PETITIONER |
IPR2015-00418 Institution Denied | Apr 21, 2017 | EXHIBIT | PETITIONER |
Current Rituxan Label | Apr 21, 2017 | EXHIBIT | PETITIONER |
Dana | Apr 21, 2017 | EXHIBIT | PETITIONER |
Solal | Apr 21, 2017 | EXHIBIT | PETITIONER |
Wadler | Apr 21, 2017 | EXHIBIT | PETITIONER |
Feugier | Apr 21, 2017 | EXHIBIT | PETITIONER |
Habermann | Apr 21, 2017 | EXHIBIT | PETITIONER |
Rituxan 1999 PDR | Apr 21, 2017 | EXHIBIT | PETITIONER |
Pat No. 5736137 | Apr 21, 2017 | EXHIBIT | PETITIONER |
DeNardo | Apr 21, 2017 | EXHIBIT | PETITIONER |
Declaration of Howard Ozer | Apr 21, 2017 | EXHIBIT | PETITIONER |
PETITION FOR INTER PARTES REVIEW | Apr 21, 2017 | PAPER | PETITIONER |